Javier Cortes, MD, PhD, of the IOB Institute of Oncology, discusses study findings that suggested pembrolizumab offered a prolonged survival benefit compared to chemotherapy for a subset of patients with previously treated metastatic triple-negative breast cancer. In the trial, high tumor-infiltrating lymphocytes were significantly associated with better clinical outcomes with the checkpoint…
In a phase III trial (OASIS-4) reported at the 2025 Annual ASCO Meeting and in the New England Journal of Medicine, Cardoso et al attempted…
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared…
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to…
Surgery provides improved long-term survival for patients with pancreatic ductal adenocarcinoma, with a benefit of avoiding metastatic disease but a potential risk for postoperative morbidity…
In a Japanese phase II study (NO LIMIT, WJOG13320G) reported in the Journal of Clinical Oncology, Kawakami et al evaluated whether first-line nivolumab plus low-dose…
Results from the phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy…
Neoadjuvant nivolumab plus chemotherapy significantly improved overall survival rates at 5 years compared with chemotherapy before surgery alone in patients with resectable non–small cell lung…
Results from the phase III VERITAC-2 showed that the PROTAC vepdegestrant could extend progression-free survival for people with previously treated estrogen receptor–positive, HER2-negative advanced b…
Results from the phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy…
The targeted combination of encorafenib and cetuximab plus mFOLFOX6 chemotherapy may be a new first-line standard of care for certain patients with advanced colorectal cancer.
